- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06370793
Ningbo Schizophrenia Cohort (NSC)
Ningbo Schizophrenia Cohort, a Longitudinal Population-based Ambispective Cohort Study
In recent years, the prevalence of schizophrenia in China has continued to grow, and the burden of disease in society has continued to rise. In order to improve the prognosis of patients with schizophrenia and reduce the risk of disease relapse or readmission, researchers established a cohort based on the Ningbo Mental Health Information System in Ningbo, a sub-provincial city in the southern wing of the Yangtze River Delta of China, with a resident population of more than 9 million, and linked it to the residents' health records, and through the data linkage obtained data on patients in the full cycle of pre-onset, diagnosis, follow-up, disease changes and death, realising full-cycle management of patients with schizophrenia.
Currently, NSC has accumulated data on more than 30,000 patients with schizophrenia and obtained multi-dimensional longitudinal information through long-term follow-up and data linkage. All diseases follow the World Health Organization International Classification of Diseases 10th Edition (ICD-10) for clinical coding, and available data include baseline demographics, past history, family history, social functioning deficit screening scale scores, risk assessment, and so on and longitudinal health information from electronic health records (EHR), providing a solid data base for future real-world studies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315000
- Ningbo University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of schizophrenia (F20)
- Aged 18-65 years at the time of diagnosis
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with Schizophrenia
|
Patients with schizophrenia identified based on exposures of interest to the study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk of circulatory system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Primary hypertension (I10), Cerebral infarction (I63), Transient cerebral ischaemic attacks and related syndromes (G45), Intracerebral haemorrhage (I61), Subarachnoid haemorrhage (I60), Hemorrhagic stroke (I60-I61), Stroke (I60-I64, I69), Pulmonary embolism (I26), Aortic aneurysm and dissection (I71), Cardiovascular disease (I20-I25), Atrial fibrillation (I48), Cardiomyopathy (I42), Peripheral vascular diseases (I73), Myocardial infarction (I21-I22), Heart failure (I50). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of endocrine system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Diabetes mellitus (E10-E14), Thyroid disorder (E00-E05, E61-E69, E07), Gout (E79, M10). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of pulmonary system and allergy diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Chronic pulmonary disease (J40-J47), Allergy (J30.1-J30.4, L23, L50.0, T78.0, T78.2, T78.4). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of gastrointestinal system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Ulcer/chronic gastritis (K22.1, K25-K28, K29.3-K29.5), Chronic liver disease (B16-B19, K70, K74, K76.6, I85), Inflammatory bowel disease (K50-K51), Diverticular disease of intestine (K57). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of musculoskeletal system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records :Connective tissue disorders (M05-M06, M08-M09, M30-M36, D86), Osteoporosis (M80-M82). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of urogenital system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Chronic kidney disease (N03, N11, N18-N19), Prostate disorders (N40). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of hematological system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : HIV/AIDS (B20-B24), Anemias (D50-D53, D55-D59, D60-D61, D63-D64). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of cancers
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
Diagnosed with cancer (C00-C43, C45-C97) in electronic health records.
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia.
|
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of neurological system diseases
Time Frame: At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records :Vision problem (H40, H25, H54), Hearing problem (H90-H91, H93.1), Migraine (G43), Epilepsy (G40-G41), Parkinson's disease (G20-G22), Multiple sclerosis (G35), Neuropathies (G50-G64). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
At least 1 year after being diagnosed with schizophrenia during the study period (2019-2023)
|
|
Risk of suicide
Time Frame: Recorded during the study period (2019-2023)
|
At least one of the following records in the Ningbo Mental Health Information System: attempted suicide, suicide, death by suicide. Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
Recorded during the study period (2019-2023)
|
|
Risk of violence
Time Frame: Recorded during the study period (2019-2023)
|
At least one of the following records in the Ningbo Mental Health Information System: causing trouble, causing an accident, committing an offence, injuring another person. Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with schizophrenia with those without schizophrenia. |
Recorded during the study period (2019-2023)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NBU-2024-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
Clinical Trials on Patient with schizophrenia without intervention
-
Yale UniversityCompleted
-
University Hospital, Strasbourg, FranceTerminated
-
Riphah International UniversityCompleted
-
Harvard Medical School (HMS and HSDM)Sangath; Beth Israel Deaconess Medical Center; National Institute of Mental Health... and other collaboratorsNot yet recruitingSchizophrenia | Schizophrenia and Related Disorders | Psychosocial Functioning
-
Dokuz Eylul UniversityThe Scientific and Technological Research Council of TurkeyCompletedSchizophrenia DisorderTurkey (Türkiye)
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPostoperative Nausea and VomitingChina
-
University of GiessenRecruitingInflammatory Bowel Disease (IBD)Germany
-
Cardenal Herrera UniversityCompleted
-
Emory UniversityNational Institute on Aging (NIA)Recruiting